Kyowa Kirin has bought back rights outside of cancer to tivozanib, amending an agreement dating back to 2006 with AVEO, and opening up the possibility of research in ophthalmology.

JPMorgan initiated coverage on Kirin Holdings Co Ltd (2503:JP) (OTC: KNBWY), assigning a Neutral rating to the company's ...

Kyowa Kirin ploughed ahead with KW-6356 despite the reservations of its former partner Lundbeck, which held the rights to KW-6356 outside Asia before handing them back to the Japanese company.

Kura Oncology (NASDAQ:KURA) stock slid 17% post-market after the company announced a collaboration deal with Japan's Kyowa Kirin (OTCPK:KNBWY) for its leukemia drug candidate ziftomenib worth up ...

The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...

Aa Aaaaaaaaa Aaa 430.57 +21.55% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...